ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update

27 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023

24 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety

22 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)

20 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences Appoints Senior VP of Regulatory Affairs

06 ноя 2023 08:00:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease

25 окт 2023 08:00:00 Источник Nasdaq GlobeNewswire

Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

14 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board

12 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results

08 авг 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety

07 авг 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023

02 авг 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023

01 авг 2023 07:30:01 Источник Nasdaq GlobeNewswire

Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome

28 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem

27 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

20 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

15 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ

12 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

06 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)

01 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

09 май 2023 07:30:01 Источник Nasdaq GlobeNewswire